论文部分内容阅读
目的：探讨联合化疗方案治疗非小细胞肺癌的临床效果。方法将60例非小细胞肺癌患者按照随机数字表法分为两组，每组30例，两组均常规予以吉西他滨、顺铂治疗，实验组在此基础上联合索拉非尼治疗，随访3 a。采用实体肿瘤疗效评价标准评估两组近期、远期治疗效果，随时记录不良反应发生状况。结果治疗后两组近期、远期治疗效果比较差异均无显著性(P >0.05)，实验组除手足综合征发生率显著高于对照组(P 0.05)。结论吉西他滨、顺铂联合索拉非尼联合化疗方案对改善非小细胞肺癌患者的总生存期和远期存活率效果不明显，临床应根据患者病理特点和生物标记物进行个体化治疗。“,”Objective To explore the efficacy of combination chemotherapy for non-small cell lung cancer (NSCLC).Methods Sixty NSCLC patients were assigned to two groups of 30 ones each according to ran-dom number table,both groups received routine gemcitabine and cisplatin treatment,on this basis experi-mental group was plus sorafenib,and followed up for 3 years.Short-and long-term treatment effective-ness were assessed with the Response Evaluation Criteria in Solid Tumors and adverse reactions recorded at any time.Results There were no significant group differences in short-and long-term treatment effec-tiveness after treatment (P >0.05),the incidence of hand-foot syndrome was significantly higher in exper-imental than in control group (P 0.05).Conclusion The combination chemotherapy of gemcitabine,cispl-atin and sorafenib has no obvious effect in improving the overall survival and long-term survival rate of NSCLC patients,individualized treatment should be given to patients according their pathological charac-teristics and biological markers.